Methods and compositions for treating cancer
AssigneeThe University of Chicago
InventorsLev BECKER, Chang CUI
Life of this patent
Estimating the term…
Abstract
Embodiments are directed to: (i) neutrophil secreted factors that have the capacity to kill a broad range of cancer cells without affecting the viability of non-cancer cells. Two neutrophil killing factors have been identified by the inventors: (1) eosinophil cationic protein (ECP) and (2) neutrophil elastase (ELANE); or (ii) therapeutic compositions that include CD95 degrading polypeptide components and methods of treating cancer with the same.
Claims43
A therapeutic composition comprising eosinophil cationic protein (ECP), neutrophil elastase (ELANE), or ECP and ELANE.
A therapeutic composition comprising a neutrophil elastase (ELANE) polypeptide, wherein the ELANE polypeptide has 150 to 260 amino acids that are at least 95% identical to the amino acid sequence of SEQ ID NO:2.
A therapeutic composition comprising a eosinophil cationic protein (ECP) polypeptide, wherein the ECP polypeptide has 100 to 155 amino acids that are at least 95% identical to the amino acid sequence of SEQ ID NO:1.
A method for killing a cancer cell by CD95 degradation comprising contacting the cancer cell with an effective amount of a protease that cleaves CD95.
A protease composition targeting CD95 degradation comprising one or more polypeptide components comprising cathepsin G (CTSG), Proteinase 3 (PRTN3), murine neutrophil elastase (mELANE), or porcine pancreatic elastase (pELA1).
Dependencies are inferred from the claim text.